Lyra Therapeutics, Inc. – NASDAQ:LYRA

Lyra Therapeutics stock price today

$7.09
+6.89
+3621.78%
Financial Health
0
1
2
3
4
5
6
7
8
9

Lyra Therapeutics stock price monthly change

-34.36%
month

Lyra Therapeutics stock price quarterly change

-34.36%
quarter

Lyra Therapeutics stock price yearly change

-96.25%
year

Lyra Therapeutics key metrics

Market Cap
11.27M
Enterprise value
45.25M
P/E
-1.3
EV/Sales
6.34
EV/EBITDA
-0.59
Price/Sales
10.59
Price/Book
0.93
PEG ratio
-0.02
EPS
-1.24
Revenue
1.68M
EBITDA
-69.92M
Income
-68.87M
Revenue Q/Q
29.75%
Revenue Y/Y
41.53%
Profit margin
-1075.72%
Oper. margin
-1090.79%
Gross margin
5.03%
EBIT margin
-1090.79%
EBITDA margin
-4162.26%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Lyra Therapeutics stock price history

Lyra Therapeutics stock forecast

Lyra Therapeutics financial statements

Lyra Therapeutics, Inc. (NASDAQ:LYRA): Profit margin
Jun 2023 458K -15.61M -3410.04%
Sep 2023 544K -15.65M -2877.02%
Dec 2023 146K -15.15M -10380.82%
Mar 2024 532K -22.45M -4220.3%
Lyra Therapeutics, Inc. (NASDAQ:LYRA): Analyst Estimates
Sep 2025 203.5K -13.71M -6740.63%
Oct 2025 118K -14.40M -12205.56%
Dec 2025 203.5K -13.20M -6487.4%
Dec 2025 118K -13.44M -11391.85%
  • Analysts Price target

  • Financials & Ratios estimates

Lyra Therapeutics, Inc. (NASDAQ:LYRA): Debt to assets
Jun 2023 125675000 27.09M 21.56%
Sep 2023 120575000 36.33M 30.14%
Dec 2023 142600000 53.18M 37.29%
Mar 2024 141527000 64.02M 45.24%
Lyra Therapeutics, Inc. (NASDAQ:LYRA): Cash Flow
Jun 2023 -14.28M -561K 47.18M
Sep 2023 -14.11M -14.97M -418K
Dec 2023 -19.05M -2.35M 18.92M
Mar 2024 -22.45M 7.85M 8.64M

Lyra Therapeutics alternative data

Lyra Therapeutics, Inc. (NASDAQ:LYRA): Employee count
Aug 2023 64
Sep 2023 73
Oct 2023 73
Nov 2023 73
Dec 2023 78
Jan 2024 78
Feb 2024 78
Mar 2024 88
Apr 2024 88
May 2024 88
Jun 2024 109
Jul 2024 109

Lyra Therapeutics other data

0.69% -51.11%
of LYRA is owned by hedge funds
207.83K -18.86M
shares is hold by hedge funds

Lyra Therapeutics, Inc. (NASDAQ:LYRA): Insider trades (number of shares)
Period Buy Sel
May 2023 10832496 0
Nov 2023 25000 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
WAKSAL HARLAN director, officer: Executive Ch..
Common Stock 25,000 $2.96 $74,100
Purchase
NBVM GP, LLC 10 percent owner
Common Stock 1,203,612 $2.43 $2,924,777
Purchase
NBVM GP, LLC 10 percent owner
Common Stock 403,858 $2.43 $981,375
Purchase
NBVM GP, LLC 10 percent owner
Common Stock 197,946 $2.43 $481,009
Purchase
NBVM GP, LLC 10 percent owner
Warrant to purchase Common Stock 601,806 $2.67 $1,608,627
Purchase
NBVM GP, LLC 10 percent owner
Warrant to purchase Common Stock 201,929 $2.67 $539,756
Purchase
NBVM GP, LLC 10 percent owner
Warrant to purchase Common Stock 98,973 $2.67 $264,555
Purchase
ANDERSON EDWARD T director, 10 percent owner:
Common Stock 1,203,612 $2.43 $2,924,777
Purchase
ANDERSON EDWARD T director, 10 percent owner:
Common Stock 403,858 $2.43 $981,375
Purchase
ANDERSON EDWARD T director, 10 percent owner:
Common Stock 197,946 $2.43 $481,009
Patent
Application
Filling date: 4 Mar 2021 Issue date: 24 Jun 2021
Application
Filling date: 7 Dec 2020 Issue date: 10 Jun 2021
Grant
Filling date: 13 Dec 2016 Issue date: 13 Apr 2021
Application
Filling date: 28 Sep 2020 Issue date: 11 Mar 2021
Grant
Filling date: 5 Nov 2018 Issue date: 15 Dec 2020
Grant
Filling date: 5 Nov 2018 Issue date: 8 Dec 2020
Application
Filling date: 20 Apr 2018 Issue date: 26 Nov 2020
Grant
Filling date: 26 Nov 2018 Issue date: 20 Oct 2020
Application
Filling date: 3 Apr 2020 Issue date: 8 Oct 2020
Application
Filling date: 7 Apr 2020 Issue date: 23 Jul 2020
Tuesday, 12 November 2024
zacks.com
globenewswire.com
Tuesday, 15 October 2024
globenewswire.com
Friday, 27 September 2024
globenewswire.com
Wednesday, 14 August 2024
zacks.com
globenewswire.com
Tuesday, 21 May 2024
globenewswire.com
Monday, 6 May 2024
investorplace.com
globenewswire.com
Tuesday, 30 April 2024
Zacks Investment Research
Sunday, 28 April 2024
Seeking Alpha
Thursday, 28 March 2024
Zacks Investment Research
Monday, 25 March 2024
Zacks Investment Research
Friday, 22 March 2024
Zacks Investment Research
Friday, 8 March 2024
Zacks Investment Research
Thursday, 29 February 2024
Zacks Investment Research
Monday, 26 February 2024
Zacks Investment Research
Wednesday, 17 January 2024
Zacks Investment Research
Wednesday, 20 December 2023
Zacks Investment Research
Monday, 11 December 2023
Zacks Investment Research
Tuesday, 10 October 2023
Seeking Alpha
Monday, 9 October 2023
Seeking Alpha
Wednesday, 13 September 2023
Zacks Investment Research
Thursday, 13 July 2023
GlobeNewsWire
Monday, 5 June 2023
24/7 Wall Street
Friday, 2 June 2023
GlobeNewsWire
Friday, 12 May 2023
Zacks Investment Research
Tuesday, 9 May 2023
GlobeNewsWire
Monday, 29 August 2022
PRNewsWire
Tuesday, 9 August 2022
Zacks Investment Research
  • What's the price of Lyra Therapeutics stock today?

    One share of Lyra Therapeutics stock can currently be purchased for approximately $7.09.

  • When is Lyra Therapeutics's next earnings date?

    Unfortunately, Lyra Therapeutics's (LYRA) next earnings date is currently unknown.

  • Does Lyra Therapeutics pay dividends?

    No, Lyra Therapeutics does not pay dividends.

  • How much money does Lyra Therapeutics make?

    Lyra Therapeutics has a market capitalization of 11.27M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 14.31% to 1.56M US dollars.

  • What is Lyra Therapeutics's stock symbol?

    Lyra Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "LYRA".

  • What is Lyra Therapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Lyra Therapeutics?

    Shares of Lyra Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Lyra Therapeutics's key executives?

    Lyra Therapeutics's management team includes the following people:

    • Dr. Maria Palasis Ph.D. Chair of the Board, Chief Executive Officer & Pres(age: 60, pay: $754,070)
    • Mr. R. Donald Elsey MBA Advisor(age: 71, pay: $536,340)
    • Dr. Robert Richard Ph.D. Senior Vice President of R&D(age: 68, pay: $366,740)
  • How many employees does Lyra Therapeutics have?

    As Jul 2024, Lyra Therapeutics employs 109 workers, which is 24% more then previous quarter.

  • When Lyra Therapeutics went public?

    Lyra Therapeutics, Inc. is publicly traded company for more then 5 years since IPO on 1 May 2020.

  • What is Lyra Therapeutics's official website?

    The official website for Lyra Therapeutics is lyratherapeutics.com.

  • Where are Lyra Therapeutics's headquarters?

    Lyra Therapeutics is headquartered at 480 Arsenal Way, Watertown, MA.

  • How can i contact Lyra Therapeutics?

    Lyra Therapeutics's mailing address is 480 Arsenal Way, Watertown, MA and company can be reached via phone at +61 73934600.

Lyra Therapeutics company profile:

Lyra Therapeutics, Inc.

lyratherapeutics.com
Exchange:

NASDAQ

Full time employees:

88

Industry:

Biotechnology

Sector:

Healthcare

Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

480 Arsenal Way
Watertown, MA 02472

CIK: 0001327273
ISIN: US55234L1052
CUSIP: 55234L105